Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 6 minute read Pharma Industry News Can Genentech’s $50 direct-to-patient Xofluza launch reshape access to flu antivirals in 2025? Genentech slashes Xofluza price by 70% in a direct-to-patient launch with Amazon, Cost Plus, and Alto Pharmacy. See how this reshapes flu access in 2025. bySrinathOctober 16, 2025